Is Hims & Hers Legit?
Hims & Hers is a large, publicly traded (NYSE: HIMS) telehealth company — that scale is itself a legitimacy signal. But the same entity holds two open FDA warning letters over compounded-GLP-1 marketing claims and an active FTC lawsuit (joined by California and Utah) alleging it shared consumers' health data with Meta and Snap despite privacy claims. Both are real, both are unresolved as of this check, and neither is offset by the company's size.
Legal entity: Hims & Hers Health, Inc.. Scored 6.1/10, ranked #32 of 37 clinics we track.
FDA warning letters on file
Hims & Hers Health, Inc. dba Hims — MARCS-CMS 716567, issued 2025-09-09 (Center for Drug Evaluation and Research (CDER)).
FDA states it reviewed hims.com in August 2025 and cites on-site claims — "Same active ingredient as Ozempic and Wegovy", "Clinically proven ingredients" — for implying the compounded semaglutide sold is the same as the FDA-approved product. FDA states compounded drugs are not FDA-approved, making the claims false or misleading and the products misbranded under FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)].
Hims & Hers Health, Inc. dba Hers — MARCS-CMS 716825, issued 2025-09-09 (Center for Drug Evaluation and Research (CDER)).
Same-day companion letter to the one above, addressed to the same parent company's forhers.com site. FDA cites claims — "Weekly injectable GLP-1 with the same active ingredient as Ozempic and Wegovy", "Clinically proven ingredients" — on the same grounds: implying FDA-approved-equivalence for a compounded, non-FDA-approved product, in violation of FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)].
This is an allegation in FDA's opening enforcement communication — not an adjudicated finding of wrongdoing. See the full picture across all 29 clinics we track →
Confirmed regulatory action on file
FTC, joined by California and Utah lawsuit against Hims & Hers Health, Inc. — filed 2026-07-29 (3:26-cv-7871 (N.D. Cal.)).
Shared consumers' sensitive health information with third-party advertising platforms owned by Meta and Snap — via customer lists and tracking technology recording on-site "Events" — despite privacy representations that this data would be protected. Also alleges Hims fails to clearly disclose that it charges consumers almost immediately after intake-form submission, and makes cancellation difficult.
Does not move Hims' transparency score further — already at the 4.0 floor from its two open FDA warning letters, shown above. Disclosed on its own because it is, on its face, a more directly on-point transparency finding than the FDA letters: sharing health data with ad platforms while claiming to protect it is squarely about trust, not a marketing-claims technicality. Same entity, same case already applied on our sister site trt-picks.com under its "hims-trt" listing.
A government enforcement action confirming or alleging deceptive billing, cancellation, or data-handling practices caps this provider's transparency score the same way an open FDA warning letter does — one cap regardless of how many actions are on file. See our editorial policy →
Third-party records
What we found outside Hims & Hers's own site — BBB, its named pharmacy partner (or lack of one), and whether it publishes a real HIPAA notice.
Better Business Bureau
Not Rated · not BBB accredited (checked 2026-08-30)
Dismissed: "Hims Inc dba Selvas BLV", Austin, TX — a retail optical-goods business, unrelated name coincidence only.
Same entity already named on the open FDA warning letters and the FTC lawsuit disclosed on this review. A second, separate BBB filing — "Hims & Hers Inc.", San Francisco, CA, also "Not Rated" — appears to be a related corporate filing, not confirmed as a duplicate.
Pharmacy partner
Inconclusive — hims.com is fully blocked, both via curl and WebFetch. Cannot confirm whether a pharmacy is named or not.
HIPAA disclosure
Inconclusive — hims.com returns HTTP 403 on every page. Cannot confirm presence or absence of a HIPAA notice.
This page states a legal/regulatory record, not a purchase recommendation. Read the full Hims & Hers review → for pricing, treatment options, and our scored verdict against every clinic we track.
A low score or an open finding is a measurement against our published rubric, not an accusation — see our editorial policy →.